Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Targeting the PD-L1 pathway with atezolizumab has demonstrated objective responses across a
broad range of malignancies including head and neck squamous cell carcinoma (SCCHN). MO39839
is a window of opportunity study investigating the feasibility, safety and postoperative
complication rates of preoperative short time immunotherapy with atezolizumab in patients
with local SCCHN. In the scope of MO39839 a comprehensive translational research program will
be conducted to assess the potential effect of atezolizumab on dynamics in tumor immunity,
and to identify and validate potential predictive and prognostic biomarkers.